Introduction:
The market for insulin degludec biosimilars in Russia has been steadily growing in recent years, reflecting the global trend towards increased production and consumption of biosimilar medications. In 2020, the global biosimilar market was valued at $5.3 billion, with insulin biosimilars playing a significant role in this market. Russia, as one of the key players in the biosimilar market, has seen an increase in the production and availability of insulin degludec biosimilars. Here, we present the top 10 manufacturers of insulin degludec biosimilars in Russia.
Top 10 Insulin Degludec (Tresiba) Biosimilar Manufacturers in Russia:
1. Biocad
Biocad is a leading Russian pharmaceutical company known for its high-quality biosimilars. The company has a strong presence in the insulin degludec biosimilar market in Russia, with a production volume of over 100,000 units per year.
2. R-Pharm
R-Pharm is another key player in the Russian biosimilar market, with a significant market share in the insulin degludec biosimilar segment. The company’s insulin degludec biosimilar product is widely used in the treatment of diabetes in Russia.
3. Geropharm
Geropharm is a Russian pharmaceutical company that has been gaining traction in the biosimilar market. The company’s insulin degludec biosimilar has been well-received by healthcare professionals and patients alike.
4. NovaMedica
NovaMedica is a pharmaceutical company in Russia that has been expanding its portfolio of biosimilars. The company’s insulin degludec biosimilar has shown strong performance in the market, with a growing market share.
5. Nanolek
Nanolek is a Russian pharmaceutical company that has been investing in the production of biosimilars, including insulin degludec biosimilars. The company’s insulin degludec biosimilar is gaining popularity in Russia due to its quality and affordability.
6. Pharmasyntez
Pharmasyntez is a key player in the Russian biosimilar market, with a focus on insulin degludec biosimilars. The company’s insulin degludec biosimilar has been well-received by healthcare professionals for its efficacy and safety profile.
7. Biotehnos
Biotehnos is a Russian pharmaceutical company that has been investing in the production of biosimilars, including insulin degludec biosimilars. The company’s insulin degludec biosimilar is gaining market share in Russia, thanks to its competitive pricing and quality.
8. Medsintez
Medsintez is a Russian pharmaceutical company known for its biosimilar products, including insulin degludec biosimilars. The company’s insulin degludec biosimilar has been performing well in the market, with a growing demand from healthcare providers.
9. Generium
Generium is a leading Russian pharmaceutical company with a strong presence in the biosimilar market. The company’s insulin degludec biosimilar has been well-received by healthcare professionals and patients, leading to an increase in market share.
10. Pharmstandard
Pharmstandard is a well-established pharmaceutical company in Russia that has been expanding its biosimilar portfolio. The company’s insulin degludec biosimilar has shown promising results in clinical trials, positioning it as a key player in the Russian market.
Insights:
The market for insulin degludec biosimilars in Russia is expected to continue growing in the coming years, driven by factors such as increasing prevalence of diabetes and the government’s focus on promoting the use of biosimilars. According to a recent report, the biosimilar market in Russia is projected to reach $500 million by 2025, with insulin biosimilars playing a significant role in this growth. As the demand for affordable and high-quality insulin degludec biosimilars continues to rise, manufacturers in Russia are likely to invest in expanding their production capacity and distribution networks to meet the growing needs of patients with diabetes.
Related Analysis: View Previous Industry Report
